A Study to Evaluate the Efficacy and Safety of Extraneal Physiological pH Compared with Current Extraneal in Patients Receiving Continuous Ambulatory Peritoneal Dialysis (CAPD).

Baxter R&D Europe SCR0 个研究点目标入组 120 人开始时间: 2004年9月13日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 120

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Patients who have given written informed consent after the nature of the study has been explained.
•2. Patients who are at least 18 years of age.
•3. Patients who have been treated with CAPD with Physioneal 40 or Dianeal PD4 and current Extraneal for at least 60 days before the baseline visit (week –2).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Patients who have received antibiotics for the treatment of an episode of peritonitis within 30 days before the screening visit (week –4). Peritonitis being defined as 2 out of 3 of the following criteria:
•a) Cloudy peritoneal effluent with peritoneal white blood cell (WBC) count > 100 cells/mm3 due predominately to neutrophils (>50%), (= 1L dialysate after = 2h dwell time).
•b) Signs and symptoms of peritoneal inflammation (e.g., abdominal pain).
•c) Demonstration of microorganism or yeast in the peritoneal effluent by culture or Gram’s stain.
•2. Patients who have had acute or chronic exit-site or tunnel infection in the past 14 days, counted from the last day of infection to the screening visit (week –4).
•3. Patients who have other serious diseases, such as active, or if previously treated, residual malignancy or systemic infection.
•4. Patients who have had a major illness or injury requiring hospitalisation within 30 days before the baseline visit (week –2).
•5. Patients who have severe malnutrition (serum albumin < 25 g/l by bromocresol green method).
•6. Patients who are participating in another study that requires Ethics Committee approval. Non-interventional studies are permitted.
•7. Patients who have received an investigational product within 30 days preceding the screening visit.
•8. Patients who are pregnant or lactating. (NB: Female patients of childbearing potential must have a negative urine or serum pregnancy test at the time of the screening and will be required to use a medically acceptable means of contraception during their participation in this study).
•9. Patients who have a significant psychiatric disorder or mental disability that could interfere with his/her ability to provide informed consent and/or comply with protocol procedures.
•10. Patients who routinely add sodium bicarbonate to the dialysis bags or uses oral sodium bicarbonate.
•11. Patients who routinely use Nutrineal (1.1% amino acid based solution) and cannot have this omitted from his/her regimen for the 10 week study period.
•12. Patients who are allergic to starch-based polymers.
•13. Patients who have glycogen storage disease.
•14. Patients who have had abdominal surgery within 30 days preceding the screening visit (V0).
•15. Patients who have had abdominal fistulae, tumours, open wounds, herniae or other conditions which compromise the integrity of the abdominal wall, abdominal surface or intra-abdominal cavity within 30 days preceding the screening visit (V0).
•16. Patients who have maltose or isomaltose intolerance.
•17. Patients who have other serious acute or active conditions that in the investigator's opinion would preclude their participation in the study.

研究者

发起方

Baxter R&D Europe SCR

相似试验

进行中（未招募）

1 期

A Study to Evaluate the Efficacy and Safety of Extraneal Physiological pH Compared with Current Extraneal in Patients Receiving Continuous Ambulatory Peritoneal Dialysis (CAPD).End Stage Renal Disease patients receiving continuous ambulatiry peritoneal dialysis (CAPD)MedDRA version: 6.1 Level: LLT Classification code 10014646

EUCTR2004-001388-23-DEBaxter R&D Europe SCR120

进行中（未招募）

1 期

EUCTR2004-001388-23-DKBaxter R&D Europe SCR120

进行中（未招募）

1 期

EUCTR2004-001388-23-GBBaxter R&D Europe SCR120

已完成

不适用

A study to evaluate the safety and efficacy of ex vivo expanded autologous gamma/delta T cell infusion following zoledronic acid sensitization in patients who received radiotherapy for bone metastases.Patients with bone metastatic cancer

JPRN-UMIN000000628niversity of Tokyo, Graduate School of Medicine10

已完成

Unknown

study on overall improvement of Skin Parameters

CTRI/2023/06/054242Transformative Learning Solutions Pvt Ltd75